Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3423 - Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). NORA trial (GECP 15/02)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Surgical Oncology;  Radiation Oncology;  Non-Small Cell Lung Cancer


Margarita Majem Tarruella


Annals of Oncology (2017) 28 (suppl_5): v457-v459. 10.1093/annonc/mdx379


M. Majem Tarruella1, L. Isla Casado2, M. Guirado3, B. Massuti Sureda4, A.L. Ortega Granados5, R. Marse Fabregat6, M. Domine Gomez7, R. de las Peñas8, M.T. Moran Bueno9, S. Vazquez Estevez10, M.A. Sala Gonzalez11, J. Coves Sarto12, J.M. Sánchez-Torres13, D. Vicente Baz14, J. Gonzalez-Larriba15, A. Paredes16, N. Farré17, L. Fernández Fornos18, A. Mena19, M. Provencio Pulla20

Author affiliations

  • 1 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 2 Medical Oncology, University Hospital Lozano Blesa, Zaragoza/ES
  • 3 Medical Oncology, Hospital General Universitario de Elche, Elche/ES
  • 4 Medical Oncology, Hospital General Universitario de Alicante, 3010 - Alicante/ES
  • 5 Oncología Médica, Complejo Hospitalario de Jaén, 23006 - Jaén/ES
  • 6 Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca/ES
  • 7 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 8 Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón/ES
  • 9 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 10 Medical Oncology, Hospital Universitario Lucus Augusti, 27003 - Lugo/ES
  • 11 Medical Oncology Department, Hospital de Basurto, 48013 - Bilbao/ES
  • 12 Medical Oncology, Hospital Son Llàtzer, 7198 - Palma de Mallorca/ES
  • 13 Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 14 Medical Oncology, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 15 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Medical Oncology, Hospital Universitario Donostia, San Sebastián/ES
  • 17 Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 18 Radiation Oncology, Hospital General Universitario de Elche, Elche/ES
  • 19 Radiation Oncology, Hospital Universitario Son Espases, Palma de Mallorca/ES
  • 20 Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 - Madrid/ES


Abstract 3423


CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of low doses of CT. mOV has shown good efficacy and improved safety, and could improve the RT effect. Our goal is to evaluate the efficacy and safety of P-mOV with radical RT in patients (pts) with LA-NSCLC.


Pts aged 18-75 years with histologically proven untreated and unresectable LA-NSCLC, adequate bone marrow, hepatic & renal function, ECOG PS0-1, received P 80mg/m2 D1 every 3 weeks combined with mOV 50mg/day on days D1, 3 & 5/weekly, 2 cycles (cy) as induction; patients without progression received 2 more cy of P at the same dose with mOV 30mg/day on D1, 3 & 5/weekly, concurrently with RT (66Gy in 6.5weeks). Primary endpoint was progression-free survival (PFS) by RECIST v1.1; secondary endpoints were: overall response rate, overall survival and safety profile. To guarantee an overall type-1 α error no greater than 0.05 and a type II (β) error 0.1 for PFS, a sample size of 67 pts was planned.


Since May 2016, 58 pts have been recruited. Fifty-three pts have been included in the analysis. Pt characteristics: Male 72%; median age 63 (range 33-75); PS 0/1 62/48%; smokers 48%; adenocarcinoma/squamous 43.4/35.9%; stage IIIA/B 35.9/58.5%. Hematological G3-4 toxicities: neutropenia 18.9%; anemia 3.8%; febrile neutropenia 7.5%. Non-hematological G3-4 toxicities: esophagitis 1.9%; infection without neutropenia 1.9%; dyspnea 3.8%; thromboembolism 3.8%. No treatment-related deaths were reported.


mOV-P administered with RT has a manageable safety profile. Based on this, accrual is ongoing.

Clinical trial identification

EudraCT 2015-003312-21.

Legal entity responsible for the study

Spanish Lung Cancer Group (SLCG)


Spanish Lung Cancer Group (SLCG)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.